Read about Endologix
in the news

Embrace the evidence.

The Latest:

Endologix Announces 36-Month Results of DETOUR2 Study at 2024 VIVA Late-Breaking Clinical Trial Session

See Release

All News

Archives

Endologix Announces First U.S. Commercial Implant of AFX®2 Bifurcated Endograft System

Endologix LLC and TriVascular Technologies, Inc. Complete Merger

Endologix AFX(R) Endovascular AAA System Receives Shonin Approval for Marketing in Japan

Endologix LLC and TriVascular Technologies, Inc. Announce Merger to Create a Leading Cardiovascular Growth Company Focused on the Treatment of Aortic Disorders